1 of 1
Story summary
- GE HealthCare agreed to acquire Sofie Biosciences for $945 million cash.
- The transaction, adding 15 U.S. sites, 21 cyclotrons and Phase III tracer FAPI-74 rights, will close in H1 2027.
- Q2 revenue reached $5.295 billion, a 3.5% organic increase YoY.
- Adjusted EPS rose to $1.13, beating the $1.05 forecast.
- Analysts set new price targets: Needham Buy at $93 and Mizuho raised its target to $85, citing 11% order growth.